Jonathan L. Diesenhaus

Jonathan L. Diesenhaus

Partner, Washington, D.C.

"He is an excellent lawyer and at the top of his game - when it's a complicated and difficult issue he is extremely good at analyzing it and communicating his recommendation. He thinks very quickly on his feet." 

Chambers USA

Jonathan Diesenhaus advises and advocates for companies and professionals in the life sciences, health care, and other regulated industries surrounding civil, criminal, as well as administrative enforcement matters.

Jonathan helps clients respond quickly and efficiently to government investigations, evaluating allegations, reviewing evidence, assessing risk, and identifying strategies to achieve the most appropriate results.

As a leading False Claims Act (FCA) litigator, he defends qui tam cases brought by whistle-blowers and the government in federal courts across the United States. Amid threats of prosecution and fines for retaining over payments, even when there was no fraud, Jonathan guides his clients through internal investigations, repayment, and, when necessary, voluntary disclosures to agencies and law enforcement. His clients include pharmaceutical and medical device companies, hospitals, physician groups, research universities, and academic medical centers.

Jonathan has been prosecuting and defending health care and government program fraud cases for over 25 years. From 1998 to 2005, he handled civil health care fraud, FCA, and qui tam cases as a senior trial counsel in the Civil Division of the U.S. Department of Justice (DOJ). He represented the government in matters that established the FCA as a vehicle to pursue violations of the Anti-Kickback Statute, the Stark Law, and the Food, Drug, and Cosmetic Act. Jonathan has received a number of awards for his work from the DOJ, the U.S. Food and Drug Administration, and the Office of Inspector General in the U.S. Department of Health and Human Services.

Jonathan also works with industry and academic trade associations to educate policymakers on the complications of prosecuting health care fraud under both state and federal qui tam statutes, on the detrimental impact of qui tam and federal FCA investigations, and the effect that litigation has on businesses and individuals.

Awards and recognitions

2014-2018

Litigation: White Collar and Government Investigations (District of Columbia)
Chambers USA

2018

Healthcare: Service Providers, Hall of Fame
Legal 500 US

2013-2018

Healthcare: Service Providers, Leading Lawyer
Legal 500 US

2014, 2016-2017

Dispute Resolution: Corporate Investigations and White-Collar Criminal Defense
Legal 500 US

2013-2018

Health Care Law
The Best Lawyers in America

2013-2018

Criminal Defense: White Collar, Civil Litigation: Defense, and Health Care
Washington, D.C. Super Lawyers

2007

Outstanding Fraud and Compliance Lawyer
Nightingale's Health Care News

2014

Martindale-Hubbell 2014 "Preeminent" (5 out of 5) Rating - Litigation, Arbitration and Employment; Health

2005

Inspector General's Integrity Award

2004

Director's Award
Executive Office of the U.S. Attorneys

2003-2004

Civil Division Special Commendations
U.S. Department of Justice

1999

Food and Drug Administration Commissioner's Special Citation

Education and admissions

Education

J.D., University of California, Berkeley Boalt Hall School of Law, 1988

B.A., University of Colorado, cum laude, 1985

Memberships

Barrister, Edward Bennett Williams Inn of Court

Member, Criminal Justice Section, White Collar Crime Committee, ABA 

Program Chair and Planning Committee Member, ABA National Institute, Health Care Fraud

Section Leadership, Health Law Section, ABA

Bar admissions and qualifications

District of Columbia

Colorado

Court admissions

U.S. Court of Appeals, District of Columbia Circuit

U.S. District Court, District of Colorado

U.S. District Court, District of Columbia

U.S. Supreme Court

Representative experience

Secured Deferred Prosecution Agreement and civil settlement for global biotech company accused of adulterating a surgical adhesion barrier.

Won summary judgment for university in qui tam accusing its anesthesiologists of billing for services they didn't provide.

Resolved criminal and civil Anti-Kickback Statute charges against small pharma company by Deferred Prosecution Agreement and civil settlement.

Defended global generic drug manufacturer in first of its kind civil money penalties settlement with OIG-HHS for misreporting Average Sales Price data.

Handling voluntary disclosures of excluded employee and billing problems for various corporate healthcare providers.

Won nine summary judgment motions and complete dismissal of wide-ranging qui tam alleging off-label promotion and violations of the Anti-Kickback Statute against a pharmaceutical manufacturer.  

Represented manufacturer of surgical sterilization equipment in FDA civil money penalties action for failure to report manufacturing quality problems.

Won dismissal of qui tam alleging that a large academic medical center’s methodology for compensating employed neurosurgeons violated the Stark Law.  

Representing hospital in federal grand jury investigation of allegations that surgeries were performed by unsupervised, unlicensed employed physicians.

Loading data